search
Back to results

ASTHMA (AntibioticS To Help Manage Asthma) Pilot Study

Primary Purpose

Asthma

Status
Completed
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
azithromycin
Sponsored by
Wisconsin Research Network
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Asthma focused on measuring Asthma, Chlamydia pneumoniae, Chlamydophila pneumoniae, Azithromycin

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: adults with stable persistent asthma and evidence for reversible airway obstruction Exclusion Criteria: macrolide allergy, pregnancy or lactation, specified comorbidities or medications

Sites / Locations

    Outcomes

    Primary Outcome Measures

    None specified (pilot study)
    Clinical outcomes measured: asthma symptoms, medication use, asthma-specific qulaity-of-life
    Serological measures: Chlamydia pneumonaie IgG, IgA by ELISA at baseline and follow up

    Secondary Outcome Measures

    Full Information

    First Posted
    October 27, 2005
    Last Updated
    October 27, 2005
    Sponsor
    Wisconsin Research Network
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00245908
    Brief Title
    ASTHMA (AntibioticS To Help Manage Asthma) Pilot Study
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    January 2002
    Overall Recruitment Status
    Completed
    Study Start Date
    September 1999 (undefined)
    Primary Completion Date
    undefined (undefined)
    Study Completion Date
    September 2002 (undefined)

    3. Sponsor/Collaborators

    Name of the Sponsor
    Wisconsin Research Network

    4. Oversight

    5. Study Description

    Brief Summary
    The ASTHMA Pilot Study is a randomized, controlled, parallel group clinical trial of 6 weekly doses of azithromycin (cumulative dose 4800 mg) or placebo as adjunctive treatment in addition to usual care for adults with stable persistent asthma, with final follow up at 3 months after completion of study medication. The hypothesis to be tested is that antibiotic treatment will improve asthma at followup, and that this improvement will be limited to patients with evidence of C. pneumoniae infection. The secondary hypothesis is that randomized, controlled treatment trials can be carried out successfully in a geographically dispersed practice-based research network.
    Detailed Description
    Asthma is a chronic inflammatory bronchial condition of unknown etiology. Decades ago many clinicians believed that infection played a major role in asthma etiology, but current expert opinion favors the view that asthma is a noninfectious condition whose root cause is inflammation. Therefore chronic antiinflammatory therapy, mainly inhaled corticosteroids, is currently advocated as primary anti-asthma treatment. It is important to recognize, however, that antiinflammatory therapy is palliative, not curative. A growing body of evidence implicates chronic bronchial infection with Chlamydia pneumoniae in the pathogenesis of asthma in both adults and children. Organism identification studies (culture and PCR) suggest that up to one-half of children with asthma may be chronically infected by C. pneumoniae, and seroepidemiologic studies in adults are consistent with chronic C. pneumoniae infection in the majority of adult-onset asthmatics. Furthermore, case reports and uncontrolled trials have provided provocative but inconclusive evidence that treatment of C. pneumoniae infection in both children and adults with asthma can favorably affect the natural history of this disorder. We propose a randomized, placebo-controlled, triple-blinded study of antichlamydial antimicrobial therapy in adult-onset asthma. Results will help to determine whether antimicrobial therapy is effective in treating some adult asthma syndromes. Positive results would have significant public health implications. Methodologies developed for use in this trial may expedite future studies in practice-based research networks.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Asthma
    Keywords
    Asthma, Chlamydia pneumoniae, Chlamydophila pneumoniae, Azithromycin

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 3
    Interventional Study Model
    Parallel Assignment
    Masking
    Double
    Allocation
    Randomized
    Enrollment
    100 (false)

    8. Arms, Groups, and Interventions

    Intervention Type
    Drug
    Intervention Name(s)
    azithromycin
    Primary Outcome Measure Information:
    Title
    None specified (pilot study)
    Title
    Clinical outcomes measured: asthma symptoms, medication use, asthma-specific qulaity-of-life
    Title
    Serological measures: Chlamydia pneumonaie IgG, IgA by ELISA at baseline and follow up

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: adults with stable persistent asthma and evidence for reversible airway obstruction Exclusion Criteria: macrolide allergy, pregnancy or lactation, specified comorbidities or medications
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    David L Hahn, MD, MS
    Organizational Affiliation
    Wisconsin Research Network
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Citations:
    PubMed Identifier
    15226283
    Citation
    Hahn DL, Plane MB. Feasibility of a practical clinical trial for asthma conducted in primary care. J Am Board Fam Pract. 2004 May-Jun;17(3):190-5. doi: 10.3122/jabfm.17.3.190.
    Results Reference
    background

    Learn more about this trial

    ASTHMA (AntibioticS To Help Manage Asthma) Pilot Study

    We'll reach out to this number within 24 hrs